Showing results (251-260 of 2,902) with videos related to

Sort By:
Pageof 291
Cancer Gene Therapy|July 24, 2002
Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancerMotoyuki Yamashita, Charles J Rosser, Jain-Hua Zhou, et al.
Cancer Gene Therapy|January 10, 2002
A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promotersH G van der Poel, J McCadden, G W Verhaegh, et al.
Cancer Gene Therapy|January 10, 2002
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cellsN Takebe, S C Zhao, A U Ural, et al.
Cancer Gene Therapy|January 10, 2002
Tissue-specific expression of a suicide gene for selective killing of neuroblastoma cells using a promoter region of the NCX geneM Narita, R Bahar, M Hatano, et al.
Cancer Gene Therapy|October 11, 2001
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant gliomaN G Rainov, C Fels, J W Droege, et al.
Cancer Gene Therapy|October 11, 2001
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase geneC M Beauséjour, N Eliopoulos, L Momparler, et al.
Cancer Gene Therapy|January 5, 2002
A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovirT Maeda, J O-Wang, H Matsubara, et al.
Cancer Gene Therapy|January 5, 2002
Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNFalpha-mediated apoptosisS Sanlioglu, G Luleci, K W Thomas
Cancer Gene Therapy|October 19, 2002
Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancerJoseph J Bennett, Keith A Delman, Bryan M Burt, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Pageof 291